PFE · 10-Q · 2026Q3 · Full report

Litigation and Legal Risk

PFIZER INC · 2026-11-03 · Importance 58 · Surprise 56

For the first nine months of 2026, Pfizer recorded $1.0 billion of charges for certain legal matters, primarily product liability and other legal expenses. The comparable charges for the first nine months of 2025 were $755 million, an increase of approximately 32%. These figures are the legal-matter adjustments included in the reconciliation of GAAP-reported to non-GAAP adjusted results.

Key facts

• For the first nine months of 2026, Pfizer's other income/deductions adjustment included $1.0 billion of charges for certain legal matters, primarily product liability and other legal expenses. source
• For the first nine months of 2025, Pfizer's other income/deductions adjustment primarily included $755 million of charges for certain legal matters, primarily product liability and other legal expenses. source
• For the third quarter of 2025, Pfizer's other income/deductions adjustment primarily included $191 million of charges for certain legal matters, primarily product liability expenses. source
• Pfizer reported lower charges for certain legal matters in Q3 2026 compared with Q3 2025. source
• Pfizer's first-nine-months 2026 results included charges for certain legal matters, contributing to an unfavorable period-over-period change in Other (income)/deductions—net. source